close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Phaxiam Therapeutics S.A.

News headline image
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
News headline image
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
Tickers PHXM
News headline image
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
Tickers PHXM
News headline image
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
Tickers PHXM
News headline image
PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
Tickers PHXM
News headline image
PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
Tickers PHXM
News headline image
TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
Tickers PHXM
News headline image
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
News headline image
PHAXIAM Receives Compliance Notice from Nasdaq
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
News headline image
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
News headline image
PHAXIAM Provides Business and Financial Update For the First Half of 2023
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
News headline image
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
News headline image
PHAXIAM Therapeutics announces the completion of its reverse share split
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
News headline image
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
From Phaxiam Therapeutics S.A.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today